SCHEMBL27179367

SCHEMBL27179367

CC(=O)N[C@@H]1CO[C@H](COCCOCCOCCOCCNC(=O)CCC(O)C(NC(=O)COCCOCCOCCNc2ccc([N+](=O)[O-])cc2[N+](=O)[O-])C(O)CCC(=O)NCCOCCOCCOCCOC[C@H]2OC[C@@H](NC(C)=O)[C@H]3OC(C)(C)O[C@H]32)[C@@H]2OC(C)(C)O[C@@H]21

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 9/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ DGAT1 O75907 6/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ KMT2A Q03164 1/20 0.31
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27179319 0.90 FOLH1 (0.37) FOLH1ALDH1A1DGAT1MAPTKDM4E
SCHEMBL27179369 0.90 ALDH1A1 (0.34) FOLH1ALDH1A1DGAT1MAPTKDM4E
SCHEMBL27179362 0.88 FOLH1 (0.33) FOLH1ALDH1A1DGAT1
SCHEMBL27179378 0.80 FOLH1 (0.36) FOLH1ALDH1A1DGAT1MAPTKDM4E
SCHEMBL27180340 0.79 MAPT (0.38) FOLH1ALDH1A1DGAT1MAPTKDM4E
SCHEMBL27180315 0.79 FOLH1 (0.35) FOLH1ALDH1A1DGAT1
SCHEMBL27179365 0.78 FOLH1 (0.32) FOLH1ALDH1A1DGAT1
SCHEMBL27180309 0.77 FOLH1 (0.35) FOLH1DGAT1
SCHEMBL26880449 0.77 MAPT (0.35) FOLH1ALDH1A1DGAT1MAPTKDM4E
SCHEMBL23705339 0.76 MAPT (0.47) FOLH1ALDH1A1DGAT1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins AVILAR THERAPEUTICS, INC. (US) 2025-05-27 — — US disclosed
US-12091402-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins AVILAR THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20240279209-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-08-22 — — US disclosed
US-20240101539-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312340-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins ASGR1, FCGR2A, FCGR3B FOLH1 1343/4885ALDH1A1 3256/4885DGAT1 1955/4885
US-20240279209-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B FOLH1 1343/4885ALDH1A1 3256/4885DGAT1 1955/4885
US-12091402-B2 Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins ASGR1, FCGR2A, FCGR3B FOLH1 1343/4885ALDH1A1 3256/4885DGAT1 1955/4885
US-20240101539-A1 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B FOLH1 1343/4885ALDH1A1 3256/4885DGAT1 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback